Hospira launched a nationwide recall of three lots of injections where glass strands were identified on the vial walls, according to an ASCA report.
The injections include one lot of Metoclopramide Injection — USP, 10 mg/2 mL — and two lots of Ondansetron Injection—USP, 4 mg/2 ML. The lots were distributed June through September of this year.
Hospira has not received any reports of adverse events associated with the recalled lots, but noted the potential for glass particles to dislodge into the solution, according to the report.
More Articles on Patient Safety:
The Power of the Checklist: How to Crete a Culture of Patient Safety at ASCs
Empowering Patients to Be Their Own Advocates in Healthcare Safety
10 Most Common General and Specific Adverse Drug Event Causes
The injections include one lot of Metoclopramide Injection — USP, 10 mg/2 mL — and two lots of Ondansetron Injection—USP, 4 mg/2 ML. The lots were distributed June through September of this year.
Hospira has not received any reports of adverse events associated with the recalled lots, but noted the potential for glass particles to dislodge into the solution, according to the report.
More Articles on Patient Safety:
The Power of the Checklist: How to Crete a Culture of Patient Safety at ASCs
Empowering Patients to Be Their Own Advocates in Healthcare Safety
10 Most Common General and Specific Adverse Drug Event Causes
